Repros Therapeutics Inc. (RPRX) Files An 8-K Regulation FD Disclosure
Item 7.01
| Regulation FD Disclosure. |
The information in this Current Report is being furnished to Item
7.01 of Form 8-K and, according to general instruction B.2.
thereunder, the information in this Current Report shall not be
deemed filed for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that Section. The information in this Current
Report shall not be incorporated by reference into any
registration statement to the Securities Act of 1933, as amended.
Representatives of Repros Therapeutics Inc., a Delaware
corporation (the Company) are presenting updates on the Companys
Proellex and Enclomiphene clinical programs to various investors
and other interested parties November 15 through November 17,
2016, in New York, NY, using slides containing the information
attached to this Current Report on Form 8-K as Exhibit 99.1.
These slides contain statements that are forward-looking
statements subject to the cautionary statement about
forward-looking statements set forth therein.
| Item 9.01 | Financial Statements and Exhibits. |
Exhibit
| Number | Description |
| 99.1 | Repros Therapeutics Slideshow |
About Repros Therapeutics Inc. (RPRX)
